Results 121 to 130 of about 83,505 (263)

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. [PDF]

Hemasphere
Eichenauer DA, André M, Borchmann P, Collins GP, Doherty I, Eich HT, Federico M, Fossa A, Hartmann S, Hutchings M, Illidge T, Kobe C, Plattel WJ, Specht L, Sureda A, Zaucha JM, Zijlstra JM, Aurer I.   +17 more
europepmc   +1 more source

Intraosseous Non-Hodgkin Lymphoma Mimicking a Periapical Lesion. [PDF]

Spec Care Dentist
Cunha LTMQ, Ramos JC, Faustino ISP, Lopes SMP, Santos-Silva AR, Vargas PA, Lopes MA.   +6 more
europepmc   +1 more source

Evolution of therapeutic paradigms in Hodgkin lymphoma: from "cure-oriented" to "functional cure". [PDF]

Front Oncol
Chen C, Guo W, Song X, Wan X, Li Z, Wang H, Bai O.   +6 more
europepmc   +1 more source

Prognostic impact of blood Epstein–Barr virus‐DNA in patients with peripheral T‐cell lymphoma, not otherwise specified

British Journal of Haematology, EarlyView.
Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon, Hyungwoo Cho, In Hye Song, Sejin Kim, So Heun Lee, Kyoungmin Lee, Shin Kim, Chan‐Sik Park, Eun Jin Chae, Kyung Won Kim, Jin‐Sook Ryu, Sang‐Wook Lee, Jaewon Hyung, Heounjeong Go, Dok Hyun Yoon   +14 more
wiley   +1 more source

Advanced Stage Hodgkin Lymphoma: A Review on Frontline Treatment Advances. [PDF]

Cancer J
Baron K, Hu B.
europepmc   +1 more source

[Hodgkin lymphoma and non-Hodgkin lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2013
openaire   +2 more sources

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Expression and prognostic impact of CD73 in classical Hodgkin lymphoma. [PDF]

Ann Hematol
Liu B, He C, Liu H, Ma G, Zhang S, Liu Y, Liu C, Li K, Wang Y, Liu Y, Yue M, Liu C, Wang X, Yin S, Li Z.   +14 more
europepmc   +1 more source

Paediatric‐onset autoimmune cytopenia: How can we reduce the long‐term mortality?

British Journal of Haematology, EarlyView.
Nathalie Aladjidi, Thierry Leblanc, Helder Fernandes, Capucine Picard, Jacinta Bustamante, Frédéric Rieux‐Laucat, Mathieu Fusaro, Maud Tusseau, Charlotte Durand‐Teyssier, Emma Cohendy, Jérôme Granel, Stéphane Ducassou, Agathe Escudier, Despina Moshous, Marc Michel, Bertrand Godeau, Sébastien Héritier, Mony Fahd, Brigitte Bader‐Meunier, Alain Fischer, Guy Leverger, All collaborators from the French Paediatric Haemato‐Immunologic CEREVANCE Network   +21 more
wiley   +1 more source

A comprehensive review of cancer‐induced cardiac wasting

British Journal of Pharmacology, EarlyView.
Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena, Muhammad Shahzeb Khan, Ulrich Keller, Lars Bullinger, Dominik P. Modest, Markus S. Anker   +5 more
wiley   +1 more source